Neurizon Files IND Application to Support HEALEY ALS Platform Trial
- Written by PR Newswire Asia - Asian Spectator
 |
Highlights:
- IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001
- The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies, and manufacturing information for NUZ-001
- The FDA has a period...
